Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

VERU LAWSUIT ALERT: Levi & Korsinsky Notifies Veru Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

VERU

NEW YORK, Jan. 19, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Veru Inc. ("Veru" or the "Company") (NASDAQ: VERU) of a class action securities lawsuit.

Levi & Korsinsky, LLP (PRNewsfoto/Levi & Korsinsky, LLP)

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Veru investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of all investors who purchased or otherwise acquired Veru Inc. common stock between May 11, 2022 and November 9, 2022, inclusive. Follow the link below to get more information and be contacted by a member of our team:

https://www.zlk.com/pslra-1/veru-lawsuit-loss-submission-form?prid=35724&wire=4

VERU investors may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: 1) the Company had withheld material adverse facts about the data from the sabizabulin Phase 3 trial and the Company's interactions with the United States Food and Drug Administration; 2) defendants misled Veru's shareholders to believe that the data from the sabizabulin Phase 3 trial was sufficient to support Emergency Use Authorization ("EUA") and even the submission of a New Drug Application without any further studies; and 3) the Company's filings concealed the true risks faced by Veru in gaining approval for its EUA request.

WHAT'S NEXT? If you suffered a loss in Veru during the relevant time frame, you have until February 6, 2023 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/veru-lawsuit-alert-levi--korsinsky-notifies-veru-inc-investors-of-a-class-action-lawsuit-and-upcoming-deadline-301725371.html

SOURCE Levi & Korsinsky, LLP



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today